Title: Chief Executive Officer
Company: Aurion Biotech
Location: Woodinville, Washington, United States
Greg Kunst, chief executive officer at Aurion Biotech, has been recognized by Marquis Who’s Who Top Executives for dedication, achievements, and leadership in biotech.
With over two decades of experience, Mr. Kunst has established himself as a leader in the biotech industry. Currently, he holds the positions of president, chief executive officer and board member at Aurion Biotech, a role he has held since 2021. Additionally, he serves on the board of Pr3vent INC since 2023 and acts as a strategic advisor at Oculogica since 2019.
Mr. Kunst’s journey began with pivotal positions at Glaukos Corporation, where he served as senior director of global market access and business development from 2015 to 2018, and later as vice president of global marketing and market access from 2018 to 2021. Prior to his tenure at Glaukos, he honed his skills at Alcon, holding the positions of global marketing director at Surgical Glaucoma from 2010 to 2013, and global marketing director at Retina Pharmaceuticals from 2013 to 2015.
Before his executive roles, Mr. Kunst gained valuable experience at Acelity from 2006 to 2010, where he served in various capacities, including director of health economics, reimbursement and market access for the Asia Pacific and Latin America regions, and global health economics manager. His career began as a project manager at CooperVision from 2003 to 2004.
Mr. Kunst’s educational background includes a Bachelor of Science in economics from Brigham Young University in 2002 and a Master of Business Administration in general management and strategy from Vanderbilt University Owen Graduate School of Management in 2006. He has also completed the Novartis Advance Program in Strategy and Communications at The Tuck School of Business at Dartmouth in 2014 and the M2 Leadership Program on the role of the leader at Novartis in 2013.
In his current role at Aurion Biotech, Mr. Kunst is responsible for capitalizing and raising funds for the company. Under his leadership, Aurion Biotech has raised $132 million over the last three years. He is also accountable for acquiring talent, developing drugs and creating appropriate development pathways. The cell therapy program he oversees began as an academic project at a university and has evolved into a full-scale program expected to move into phase three trials next year. The program aims to receive approval from major markets upon completion of the trials.
Mr. Kunst attributes his success to his father, a successful entrepreneur, whose achievements inspired him to work diligently and achieve his goals. Witnessing the impact of his work on patients has motivated him to make a difference in people’s lives. His career highlights include his tenure at Glaukos, where he played a pivotal role in expanding the company’s revenue from zero to $300 million and expanding its presence to more than 20 countries. He is currently focused on developing a new cell therapy to combat corneal blindness worldwide.
In his spare time, Mr. Kunst enjoys skiing and spending time with his family and dogs. He is a member of Ophthalmic World Leaders, the American-European Congress of Ophthalmic Surgery and serves on the Steering Committee of the Gavin Herbert Eye Institute at the University of California Irvine, reflecting his commitment to both professional excellence and personal fulfillment. With a proven track record of leadership and innovation in the biotech industry, he continues to drive impactful advancements that positively influence patient care and global health.
For more information, please visit:
Contact Mr. Kunst:
